Contributions
Abstract: P406
Type: Poster
Abstract Category: Clinical aspects of MS - 10 Neuro-ophthalmology
Background: Visual disorders are frequently characterised by optic nerve and retinal dysfunction. One of the classic resulting signs are visual field defects. Careful clinical evaluation is essential to rule in the diagnosis, prognosis and monitoring of such disorders. Currently, the routine assessment consist of the Humphrey's test, but it's time consuming and not widely available outside of specialist ophthalmology clinic.
Objective: To develop a smartphone application capable of assessing the visual field in order to ultimately diagnose and monitor visual impairment in resource poor settings and be used as a self-monitoring tool for people with Multiple Sclerosis.
Method: This pilot study assessed 23 eyes from volunteer patient coming initially for a follow-up in the Royal London Hospital eye clinic. Once results collected, we divided the visual field in 54 zones and compared only the “black zone”, considered as non visualized zone, one after the other. Finally, results were displayed as percentage of match.
Results: Six eyes showed a perfect reliability with 100% match, three others presented 50% of reproductivity while three more showed results ranging from 20% to 35%. Finally, 11 obtained a result lower than 20%. The latter is due to an excess of fixation loss, as the reliability of the visual when fixation loss is < 50% is clearly improved (p=0.01).
Conclusion: We developed an easy to use smartphone application capable of assessing visual fields. The results showed a promising reliability between Humphrey's tests and the visual App. However the rate of fixation loss still need to be reduced to increase their reliability.
Disclosure:
Nicolas Dubuisson is an ECTRIMS fellow, which is unrelated to the contents of this publication.
Adam Paterson has no disclosure
Mark Westcott has no disclosure
Benjamin Turner has received travel grants and consultant fees for attending advisory boards from Biogen-Idec, TEVA, Merck-Serono, Novartis and Genzyme.
David Baker is a founder and consultant to Canbex therapeutics and has received research funds from Canbex therapeutics, Sanofi-Genzyme, and Takeda in the past 3 years.
Gavin Giovannoni has received compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma, and Vertex Pharmaceuticals.
Alison Thomson received honoraria for presentations from Novartis and non-promotional educational grants from Genzyme, Novartis and Biogen, which are unrelated to the contents of this publication.
Abstract: P406
Type: Poster
Abstract Category: Clinical aspects of MS - 10 Neuro-ophthalmology
Background: Visual disorders are frequently characterised by optic nerve and retinal dysfunction. One of the classic resulting signs are visual field defects. Careful clinical evaluation is essential to rule in the diagnosis, prognosis and monitoring of such disorders. Currently, the routine assessment consist of the Humphrey's test, but it's time consuming and not widely available outside of specialist ophthalmology clinic.
Objective: To develop a smartphone application capable of assessing the visual field in order to ultimately diagnose and monitor visual impairment in resource poor settings and be used as a self-monitoring tool for people with Multiple Sclerosis.
Method: This pilot study assessed 23 eyes from volunteer patient coming initially for a follow-up in the Royal London Hospital eye clinic. Once results collected, we divided the visual field in 54 zones and compared only the “black zone”, considered as non visualized zone, one after the other. Finally, results were displayed as percentage of match.
Results: Six eyes showed a perfect reliability with 100% match, three others presented 50% of reproductivity while three more showed results ranging from 20% to 35%. Finally, 11 obtained a result lower than 20%. The latter is due to an excess of fixation loss, as the reliability of the visual when fixation loss is < 50% is clearly improved (p=0.01).
Conclusion: We developed an easy to use smartphone application capable of assessing visual fields. The results showed a promising reliability between Humphrey's tests and the visual App. However the rate of fixation loss still need to be reduced to increase their reliability.
Disclosure:
Nicolas Dubuisson is an ECTRIMS fellow, which is unrelated to the contents of this publication.
Adam Paterson has no disclosure
Mark Westcott has no disclosure
Benjamin Turner has received travel grants and consultant fees for attending advisory boards from Biogen-Idec, TEVA, Merck-Serono, Novartis and Genzyme.
David Baker is a founder and consultant to Canbex therapeutics and has received research funds from Canbex therapeutics, Sanofi-Genzyme, and Takeda in the past 3 years.
Gavin Giovannoni has received compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma, and Vertex Pharmaceuticals.
Alison Thomson received honoraria for presentations from Novartis and non-promotional educational grants from Genzyme, Novartis and Biogen, which are unrelated to the contents of this publication.